The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.
Pharmaceutical company Biontech plans to create a vaccine for malaria based on the same mRNA technology as the firm's vaccine for covid-19, which the German company developed in collaboration with Pfizer.
The US FDA has given biotech firm Saniona's drug candidate Tesomet priority status as an orphan drug for treating hypothalamic obesity. Earlier this year, Tesomet received the same priority status as a treatment for Prader-Willi syndrome.
89 percent of the Swedish population above the age of 65 are fully vaccinated, meaning authorities in Sweden are phasing out the use of the AstraZeneca vaccine. In Stockholm, residents now have a choice of vaccines.
In less than a year, Danish biotech company Hemab, which builds on technology developed by Novo Nordisk and Genmab, has gone from seed investments to a large capital fund raising round – and now to clinical trials.
Johnson & Johnson's sales figures for Darzalex in the second quarter are so good that Genmab, which developed the drug, may increase its financial expectations for the year, says senior analyst Søren Løntoft Hansen.
While Leo Pharma waits for a response to its approval application for eczema treatment Adtralza in the US, it is launching the treatment in the EU, where Head of Europe Monica Shaw can put the experience from launching psoriaris treatment Kyntheum to good use.
The two pharmaceutical companies have been forced to announce that the FDA's processing of Olumiant as a treatment for atopic dermatitis has been delayed for a second time. This is due to questions surrounding the drug class.